Otsuka’s ADHD asset succeeds in registrational trials with children and teens

Ot­su­ka Phar­ma­ceu­ti­cal’s AD­HD drug can­di­date has met its goal in a pair of Phase III tri­als fo­cused on chil­dren and teens with the neu­rode­vel­op­men­tal con­di­tion, spark­ing reg­u­la­to­ry fil­ing plans.

Cen­tanafa­dine is a nor­ep­i­neph­rine, dopamine and sero­tonin re­up­take in­hibitor. Last month, Jef­feries an­a­lysts said AD­HD prod­ucts have pre­vi­ous­ly hit peak sales of near­ly $4 bil­lion, so pos­i­tive cen­tanafa­dine da­ta would be a “very sig­nif­i­cant cat­a­lyst” for Ot­su­ka.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.